<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03222765</url>
  </required_header>
  <id_info>
    <org_study_id>EU-FP7 279074</org_study_id>
    <nct_id>NCT03222765</nct_id>
  </id_info>
  <brief_title>Prevention of Microvascular Complications in Prediabetes e-PREDICE Study</brief_title>
  <acronym>ePREDICE</acronym>
  <official_title>Early Prevention of Diabetes Complications in People With Hyperglycaemia in Europe: e-PREDICE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evidem Consultores SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Evidem Consultores SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: A significant proportion of pre-diabetics, show macro and micro vascular
      complications associated with hyperglycaemia. Although many trials have demonstrated the
      efficacy of lifestyle and pharmaceutical interventions in diabetes prevention, no trial has
      evaluated the extent to which mid- and long-term complications can be prevented by early
      interventions on hyperglycaemia.

      Aims: To assess the long-term effects on multiple complications of hyperglycaemia of early
      intensive management of hyperglycaemia with linagliptin, metformin or their combination added
      to lifestyle intervention (LSI) (diet and physical activity), compared with LSI alone in
      adults with non-diabetic intermediate hyperglycaemia (IFG, IGT or both).

      Study Design: Investigator initiated (non-commercial), long-term, multi-centre, randomised,
      partially double blinded, placebo controlled, phase-IIIb clinical trial with prospective
      blinded outcome evaluation. Participants will be randomised to four parallel arms: 1) LSI + 2
      placebo tablets/day; 2) LSI + 2 Metformin tablets of 850 mg/day; 3) LSI + 1 Linagliptin
      tablets of 5 mg/day and 1 placebo; 4) LSI + 2 tablets of a fixed-dose combination of
      Linagliptin 2.5mg and Metformin 850 /day. Active intervention will last for at least 2 years.

      Setting and population: Males and Females with pre-diabetes (IFG, IGT or both) aged 45 to 74
      years selected from primary care screening programs in 14 clinical centres from 10 countries:
      Australia, Austria, Bulgaria, Greece, Italy, Kuwait, Poland, Serbia, Spain and Turkey and .
      (N=1000)

      Main Outcomes: The primary endpoint is a combined continous variable: &quot;the microvascular
      complication Ã­ndex&quot; (MCI) composed by a linear combination of the Early Treatment Diabetic
      Retinopathy Study Scale (ETDRS) score (based on retinograms), the level of urinary albumin to
      creatinine ratio, and a measure of distal small fibre neuropathy (sudomotor test by
      SUDOSCAN), measured during baseline visit and at 24th and 48th month visits after
      randomisation. In addition, serological biomarkers of inflammation, vascular damage,
      non-alcoholic fatty liver disease, insulin secretion, measures of quality of life, sleep
      quality, neuropsychological evaluation and endothelial function will be also evaluated in a
      subset of participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, parallel , single-blind, placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Two groups (linagliptin vs placebo) double-blind Two groups (metformin &amp; metformin+linagliptin) single-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Microvascular Complication Index &quot;MIC&quot; :</measure>
    <time_frame>2-year</time_frame>
    <description>linear combination of three continous variables: ETRSD score, UACR and sudomotor index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetic Retinopathy: Scale ETDRS</measure>
    <time_frame>2-year</time_frame>
    <description>ETDRS Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine albumin to creatinine ratio (UACR)</measure>
    <time_frame>2-year</time_frame>
    <description>Ratio albumin to creatinine in mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sudomotor Index</measure>
    <time_frame>2-year</time_frame>
    <description>SUDOSCAN sweat function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of diabetes</measure>
    <time_frame>2-year</time_frame>
    <description>new cases of Type 2 Diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial dysfunction</measure>
    <time_frame>2-year</time_frame>
    <description>ENDOPATH measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>2-year</time_frame>
    <description>Insulin secretion and beta-cell function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation biomarkers</measure>
    <time_frame>2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAFLD biomarkers</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2-year</time_frame>
    <description>D15 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive function</measure>
    <time_frame>2-year</time_frame>
    <description>MMSE questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depressive symptoms</measure>
    <time_frame>2-year</time_frame>
    <description>WHO-MINI questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo
Lifestyle modification (diet and physical activity recommendations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin
Lifestyle modification (diet and physical activity recommendations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin
Lifestyle modification (diet and physical activity recommendations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin and Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination of Linagliptin and metformin
Lifestyle modification (diet and physical activity recommendations)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, metformin, linagliptin, linagliptin + metformin</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_label>Linagliptin and Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Impaired Fasting Glucose (IFG): Fasting Plasma Glucose (FPG) 6.1 to 6.9mmol/l and
             2-hour Plasma Glucose (2-h PG): &lt;7.8mmol/L;

          -  Impaired Glucose Tolerance (IGT): FPG &lt;7.0mmol/L and 2h PG &gt;_7.8 and &lt;11.1 mmol/L
             -Informed consent given

        Exclusion Criteria:

          -  Type 1 diabetes (T1D)

          -  known or screen-detected Type 2 diabetes (T2D).

          -  Use of any anti-diabetic drug within the 3 months prior to inclusion.

          -  Previous cardiovascular event, stroke or revascularization procedure of any arterial
             territory

          -  Morbid obesity (BMI&gt;45)

          -  Current renal replacement therapy.

          -  Renal function impairment: GFR &lt;60 ml/min/1.73m2.

          -  Previous diagnosis of liver cirrhosis or chronic hepatitis

          -  Elevation of liver enzymes (AST/AST) &gt;3 times of the upper normal ranges** (6m or BL).

          -  Previous diagnosis of acute or chronic pancreatitis

          -  Elevation of pancreatic enzymes (Amylase/Lipase) &gt;3 times of the upper normal ranges
             (6m or BL).

          -  Previous diagnosis of Chronic Heart Failure (NYHA class III or higher).

          -  Organ transplant or waiting for organ transplant.

          -  Diagnosis of malignant neoplasm requiring chemotherapy, surgery, radiation or
             palliative therapy in the previous 5 years.

          -  End-stage or metastatic cancer.

          -  Known or suspected hypersensitivity to trial products or related products.

          -  Known use of non prescribed narcotics or illicit drugs.

          -  Simultaneous participation in any other clinical trial of an investigational agent.

          -  Females of childbearing potential who are pregnant, breast-feeding or intend to become
             pregnant.

          -  Cataract that impedes the retinal evaluation of both eyes.

          -  Ocular surgery planned in the next 6 months

          -  Concomitant intraocular treatment (retina or choroid).

          -  Tropicamide allergy

          -  Participants with screen retinogram not optimal for retinal assessment

          -  Complete amputation of one/ both hands or one/both feet.

          -  Dementia, mental disorder or evident cognitive impairment unable to give informed
             consent.

          -  Institutionalization (nursing/mental health home, hospital, prison, etc).

          -  Suspected renal artery stenosis Recent gastrointestinal bleeding (within the last
             year)

          -  Any circumstance where ongoing medication might lead to potential adverse drug effect.

          -  Any other acute condition or exacerbation of chronic condition that in the
             investigator's opinion would interfere with the trial initiation or visit schedules or
             procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Gabriel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evidem Consultores SL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaakko Tuomilehto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evidem Consultores SL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nisa Boukichou, Ms</last_name>
    <phone>+34914025066</phone>
    <email>nisa@ceiis.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margarita Alonso, MS</last_name>
    <phone>+34914025066</phone>
    <email>mgalonso@ceiis.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Salud Jose Marva</name>
      <address>
        <city>Madrid</city>
        <zip>28030</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Sanchez, MD</last_name>
      <phone>+34629</phone>
    </contact>
    <contact_backup>
      <last_name>Ana M Santos</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.epredice.eu</url>
    <description>Webpage ePREDICE Project</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prediabetes lifestyle drugs microvascular complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.epredice.eu</doc_url>
      <doc_comment>Study Protocol Version 5.0</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

